To read the full story, subscribe or sign in.

Paradigm raises AU$66M to fund pivotal trials for Zilosul for pain associated with knee osteoarthritis

Aug. 16, 2022

Paradigm Biopharmaceuticals Ltd. announced a AU$66 million (US$46.39 million) capital raise to fund its phase III pivotal trial for injectable Zilosul (pentosan polysulfate) to treat osteoarthritis of the knee.

BioWorld BioWorld Asia Financings Inflammatory Australia

Today's news in brief

BioWorld

BioWorld briefs for Aug. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 19, 2025.

CSL to shave off 3,000 jobs, Seqirus vaccine unit

BioWorld

CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than...

Handshake with dollar sign and checkmark

Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal

BioWorld

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck...

Woman measuring her body fat with caliper

GI blow: Viking soldiers on with midstage oral obesity bid

BioWorld

Rates of adverse events (AEs) gave pause to some on Wall Street, and shares of Viking Therapeutics Inc. (NASDAQ:VKTX) fell 42%, or $17.73, to close Aug. 19 at...